213 related articles for article (PubMed ID: 33130898)
1. DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival.
Dejaegher J; Solie L; Hunin Z; Sciot R; Capper D; Siewert C; Van Cauter S; Wilms G; van Loon J; Ectors N; Fieuws S; Pfister SM; Van Gool SW; De Vleeschouwer S
Neuro Oncol; 2021 Feb; 23(2):240-250. PubMed ID: 33130898
[TBL] [Abstract][Full Text] [Related]
2. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
[TBL] [Abstract][Full Text] [Related]
3. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
4. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
5. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
6. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
10.
Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
[No Abstract] [Full Text] [Related]
11. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
13. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma.
Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ
Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698
[TBL] [Abstract][Full Text] [Related]
14. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
[TBL] [Abstract][Full Text] [Related]
16. Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Dubinski D; Won SY; Rauch M; Behmanesh B; Ngassam LDC; Baumgarten P; Senft C; Harter PN; Bernstock JD; Freiman TM; Seifert V; Gessler F
Front Immunol; 2021; 12():627650. PubMed ID: 33868245
[TBL] [Abstract][Full Text] [Related]
17. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes.
Kessler T; Berberich A; Sadik A; Sahm F; Gorlia T; Meisner C; Hoffmann DC; Wick A; Kickingereder P; Rübmann P; Bendszus M; Opitz C; Weller M; van den Bent M; Stupp R; Winkler F; Brandes A; von Deimling A; Platten M; Wick W
Cancer Med; 2020 Nov; 9(22):8373-8385. PubMed ID: 32991787
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
19. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).
Leibetseder A; Ackerl M; Flechl B; Wöhrer A; Widhalm G; Dieckmann K; Kreinecker SS; Pichler J; Hainfellner J; Preusser M; Marosi C
Neuro Oncol; 2013 Jan; 15(1):112-21. PubMed ID: 23223340
[TBL] [Abstract][Full Text] [Related]
20. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]